专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2018209211A1 ENGINEERED PRIMATE CYSTINE/CYSTEINE DEGRADING ENZYMES FOR THERAPEUTIC USES 审中-公开
公开(公告)号：WO2018209211A1
公开(公告)日：2018-11-15
申请号：PCT/US2018/032286
申请日：2018-05-11
申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
发明人： GEORGIOU, George , STONE, Everett , CRAMER, Shira
IPC分类号： C12N9/88 , A61K38/51
CPC分类号： C12N9/88 , A61B17/225 , A61K9/0019 , A61K31/7076 , A61K38/00 , A61K38/16 , A61K38/38 , A61K38/51 , A61K45/06 , A61K47/60 , A61K47/61 , A61P35/00 , C07K14/001 , C07K14/76 , C07K2319/00 , C07K2319/30 , C12Y404/01001 , A61K2300/00
摘要： Methods and compositions related to the engineering of a protein with L-cyst(e)ine degrading enzyme activity are described. For example, disclosed are modified cystathionine- ϒ- lyases comprising one or more amino acid substitutions and capable of degrading L- cyst(e)ine. Furthermore, compositions and methods are provided for the treatment of cancer and cystinuria using the disclosed modified enzymes or nucleic acids encoding said enzymes.

2. 发明申请

WO2017013183A1 COMPOSITIONS FOR PROTECTING SKIN COMPRISING DNA REPAIR ENZYMES AND PHYCOBILIPROTEIN 审中-公开
标题翻译：用于保护包含DNA修复酶和蛋白胆固醇的皮肤的组合物
公开(公告)号：WO2017013183A1
公开(公告)日：2017-01-26
申请号：PCT/EP2016/067328
申请日：2016-07-20
申请人： GREENALTECH, S.L
发明人： RUIZ CANOVAS, Eugenia , LÓPEZ CERRO, María Teresa , LATIL DE ROS, Derek Georges , DURANY TURK, Olga , SEGURA DE YEBRA, Jordi , MERCADÉ ROCA, Jaume
IPC分类号： A61K8/66 , A61Q17/04 , A61Q19/08 , A61P17/00 , A61P29/00 , A61P35/00 , A61K35/748
CPC分类号： A61K8/66 , A61K35/748 , A61K38/164 , A61K38/51 , A61Q17/04 , A61Q19/08 , C12Y401/99003
摘要： The invention relates to compositions for repairing the adverse effects of the environment daily stress, sun exposure or premature-aging on human skin which comprise a DNA repair enzyme and a phycobiliprotein.
摘要翻译：本发明涉及用于修复环境日常压力，阳光暴晒或过早老化对包括DNA修复酶和藻胆蛋白的人皮肤的不利影响的组合物。

3. 发明申请

WO2016165604A1 一种广谱的链球菌裂解酶及其应用审中-公开
公开(公告)号：WO2016165604A1
公开(公告)日：2016-10-20
申请号：PCT/CN2016/079043
申请日：2016-04-12
申请人：武汉菲吉乐科生物科技有限公司
发明人：危宏平 , 杨航 , 王靖 , 余军平
IPC分类号： C12N9/88 , C12N15/60 , A61K38/51 , A61P31/04 , A61P1/02
CPC分类号： A61K38/51 , A61P31/04 , C12N9/88 , C12N15/101 , C12N15/70
摘要：提供一种能杀灭多种链球菌、肠球菌和金黄色葡萄球菌的裂解酶ClyR及其应用。

4. 发明申请

WO2016109899A1 ALLOSTERIC ACTIVATORS FOR TREATMENT OF PHENYLKETONURIA 审中-公开
标题翻译：用于治疗苯丙酮的单药激活剂
公开(公告)号：WO2016109899A1
公开(公告)日：2016-07-14
申请号：PCT/CA2016/050017
申请日：2016-01-08
申请人： MCMASTER UNIVERSITY
发明人： BRITZ-MCKIBBIN, Philip
IPC分类号： A61K31/192 , A61K31/519 , A61K47/48 , A61P3/00 , C07C62/04 , C07C62/32 , C12Q1/00 , C12Q1/26
CPC分类号： A61K31/215 , A61K31/19 , A61K31/191 , A61K31/192 , A61K31/519 , A61K38/51 , A61P3/00 , A61P43/00 , C12Q1/00 , C12Q1/26 , C12Y114/16001 , A61K2300/00
摘要： A method of restoring activity in phenylalanine hydroxylase is provided. The method comprises exposing the phenylalanine hydroxylase to shikimic acid, a functionally equivalent analogue thereof, a pharmaceutically acceptable salt of shikimic acid or analogue thereof, or combinations thereof, A method of screening for allosteric activators for a target enzyme is also provided comprising the steps of: denaturing the target enzyme with a first chaotropic agent to yield denatured enzyme, incubating the denatured enzyme with a candidate compound under denaturing conditions to allow enzyme refolding, and assaying enzyme activity in the presence of enzyme substrate and a candidate compound; and if enzyme activity of the denatured enzyme was restored in step i) by at least about 10% of residual enzyme activity, denaturing the target enzyme with a second chaotropic agent to yield denatured enzyme, incubating the denatured enzyme with the candidate compound under non-denaturing conditions to allow enzyme refolding, and assaying enzyme activity in the presence of enzyme substrate and the candidate compound, wherein an increase in enzyme activity of at least about 10% of residual enzyme activity indicates that the candidate compound is an allosteric activator of the target enzyme.
摘要翻译：提供了恢复苯丙氨酸羟化酶活性的方法。该方法包括将苯丙氨酸羟化酶暴露于莽草酸，其功能上等同的类似物，莽草酸或其类似物的药学上可接受的盐或其组合。还提供筛选靶酶的变构激活剂的方法，包括以下步骤：：用第一离液剂变性目标酶以产生变性酶，在变性条件下将变性酶与候选化合物孵育以允许酶重折叠，并在酶底物和候选化合物存在下测定酶活性; 并且如果在步骤i）中将变性酶的酶活性恢复至少约10％的残留酶活性，则用第二离液剂对目标酶进行变性以产生变性酶，将变性酶与候选化合物在非 - 变性条件以允许酶重折叠，以及在酶底物和候选化合物存在下测定酶活性，其中酶活性的增加至少为残余酶活性的约10％表明候选化合物是靶的变构激活剂酶。

5. 发明申请

WO2015031726A3 ENGINEERED PRIMATE L-METHIONINASE FOR THERAPEUTIC PURPOSES 审中-公开
标题翻译：用于治疗目的的工程化的原始L-甲硫氨酸酶
公开(公告)号：WO2015031726A3
公开(公告)日：2015-12-10
申请号：PCT/US2014053359
申请日：2014-08-29
申请人： UNIV TEXAS
发明人： GEORGIOU GEORGE , STONE EVERETT , LU WEI-CHENG
IPC分类号： C12N15/60
CPC分类号： C12N9/88 , A61K35/12 , A61K38/51 , A61K45/06 , C12N1/14 , C12N1/20 , C12N5/0601 , C12N15/70 , C12N15/74 , C12N15/79 , C12Y404/01001 , A61K2300/00
摘要： Methods and compositions relating to the engineering of an improved protein with methionine-γ-lyase enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-γ-lyase (CGL) comprising one or more amino acid substitutions and capable of degrading methionine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with methionine depletion using the disclosed proteins or nucleic acids.
摘要翻译：描述了与具有甲硫氨酸-γ-裂解酶酶活性的改良蛋白质的工程有关的方法和组合物。例如，在某些方面，可以公开包含一个或多个氨基酸取代并能够降解甲硫氨酸的修饰的胱硫醚-γ-裂解酶（CGL）。此外，本发明的某些方面提供了使用所公开的蛋白质或核酸治疗患有甲硫氨酸缺失的癌症的组合物和方法。

6. 发明申请

WO2015054649A3 AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF OPIOID INDUCED DYSFUNCTIONS 审中-公开
标题翻译：用于治疗阿片样物质诱导性功能的冠状动脉循环的有效性
公开(公告)号：WO2015054649A3
公开(公告)日：2015-08-06
申请号：PCT/US2014060157
申请日：2014-10-10
申请人： SYNERGY PHARMACEUTICALS INC
发明人： SHAILUBHAI KUNWAR , PALEJWALA VASEEM
IPC分类号： A61K38/10 , A61K38/00 , A61K38/12
CPC分类号： A61K38/10 , A61K31/135 , A61K31/192 , A61K31/222 , A61K31/4468 , A61K31/451 , A61K31/485 , A61K31/519 , A61K31/53 , A61K38/04 , A61K38/51 , A61K45/06 , A61K2300/00
摘要： The disclosure provides a method to prevent, control, and/or treat opioid induced dysfunctions comprising administering to a patient in need a guanylate cyclase receptor agonist (GCRA) peptide. Compositions comprising guanylate cyclase receptor agonist (GCRA) peptides, methods of making, and methods of treatment are also disclosed. Further disclosed are the guanylate cyclase receptor agonist (GCRA) peptide and opioid formulated in the same composition.
摘要翻译：本公开提供了一种预防，控制和/或治疗阿片样物质诱导的功能障碍的方法，包括向需要的患者施用鸟苷酸环化酶受体激动剂（GCRA）肽。还公开了包含鸟苷酸环化酶受体激动剂（GCRA）肽，制备方法和治疗方法的组合物。还公开了以相同组成配制的鸟苷酸环化酶受体激动剂（GCRA）肽和阿片样物质。

7. 发明申请

WO2015106295A2 ENOLASE 1 (ENO1) COMPOSITIONS AND USES THEREOF 审中-公开
标题翻译： ENOLASE 1（ENO1）组合物及其用途
公开(公告)号：WO2015106295A2
公开(公告)日：2015-07-16
申请号：PCT/US2015011275
申请日：2015-01-13
申请人： BERG LLC , NARAIN NIVEN RAJIN , SARANGARAJAN RANGAPRASAD , VISHNUDAS VIVEK K , GESTA STEPHANE , JING ENXUAN
发明人： NARAIN NIVEN RAJIN , SARANGARAJAN RANGAPRASAD , VISHNUDAS VIVEK K , GESTA STEPHANE , JING ENXUAN
IPC分类号： A61K38/51 , A61K48/00
CPC分类号： A61K38/51 , A61K9/0019 , A61K9/0053 , A61K38/00 , A61K47/48246 , A61K47/59 , A61K47/64 , A61K49/0008 , C12N9/88 , C12Q1/54 , C12Y402/01011 , G01N2333/988 , G01N2800/042
摘要： The invention provides compositions comprising Eno1 for delivery to a muscle. Further, the invention provides a method for normalizing blood glucose in a subject with elevated blood glucose, comprising administering to the subject enolase 1 (Eno1), thereby normalizing blood glucose in the subject. The invention also provides methods of treating one or more conditions including impaired glucose tolerance, insulin resistance, pre-diabetes, and diabetes, especially type 2 diabetes in a subject, comprising administering to the subject enolase 1 (Eno1), thereby treating the condition in the subject. In certain methods of the invention, the Eno1 is delivered to muscle.
摘要翻译：本发明提供了用于递送至肌肉的包含Eno1的组合物。此外，本发明提供了用于使血糖升高的受试者中的血糖正常化的方法，其包括向受试者施用烯醇酶1（Eno1），从而使受试者中的血糖正常化。本发明还提供了治疗一个或多个病症的方法，所述病症包括受试者中的葡萄糖耐量受损，胰岛素抵抗，前驱糖尿病和糖尿病，尤其是2型糖尿病，包括向受试者施用烯醇酶1（Eno1），由此治疗主题。在本发明的某些方法中，Eno1被递送至肌肉。

8. 发明申请

WO2014123749A1 COMPOSITIONS AND METHODS FOR TREATING COMPLICATIONS ASSOCIATED WITH DIABETES 审中-公开
标题翻译：用于治疗与糖尿病相关的并发症的组合物和方法
公开(公告)号：WO2014123749A1
公开(公告)日：2014-08-14
申请号：PCT/US2014/013833
申请日：2014-01-30
申请人： BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
发明人： BIDASEE, Keshore, R.
IPC分类号： C12N15/52
CPC分类号： A61K38/51 , A61K48/00 , C12N9/88 , C12Y404/01005
摘要： Compositions and methods for inhibiting diabetes-related complications are provided. Several publications and patent documents are cited throughout the specification in order to describe the state of the art to which this invention pertains. Each of these citations is incorporated herein by reference as though set forth in full. Varying duration insulins, insulin delivery pumps, glucose monitoring 25 devices, food management, and exercise strategies are available to the more than 1.3 million individuals in the USA with Type 1 diabetes (TID), to maintain their blood glucose at near physiological levels.
摘要翻译：提供了抑制糖尿病相关并发症的组合物和方法。为了描述本发明所属领域的现状，在整个说明书中引用了许多出版物和专利文献。这些引用中的每一篇通过引用并入本文，如同完全阐述一样。在美国，1型糖尿病（TID）的130多万人可以使用不同时间的胰岛素，胰岛素输送泵，葡萄糖监测仪器，食品管理和运动策略，以保持其血糖接近生理水平。

9. 发明申请

WO2014113648A1 CRYSTALLIZED OXALATE DECARBOXYLASE AND METHODS OF USE 审中-公开
标题翻译：结晶氧化脱乙酰酶及其使用方法
公开(公告)号：WO2014113648A1
公开(公告)日：2014-07-24
申请号：PCT/US2014/012008
申请日：2014-01-17
申请人： ALLENA PHARMACEUTICALS, INC.
发明人： GREENE, Jack , JOHNSON, Richard , KRISHINSKIE, Dennis , SHENOY, Bhami
IPC分类号： A61K38/51 , C12N9/00 , C12N9/88
CPC分类号： C12Y401/01002 , A61K9/1623 , A61K9/1635 , A61K9/1647 , A61K9/1652 , A61K38/00 , A61K38/51 , C12N9/88
摘要： Pharmaceutical compositions comprising spray-dried oxalate decarboxylase crystals are disclosed. Methods to treat a disorder associated with elevated oxalate concentration using compositions comprising spray-dried oxalate decarboxylase crystals are also disclosed.
摘要翻译：公开了包含喷雾干燥的草酸脱羧酶晶体的药物组合物。还公开了使用包含喷雾干燥的草酸脱羧酶晶体的组合物治疗与草酸盐浓度升高相关的病症的方法。

10. 发明申请

WO2014078911A1 COMPOSITIONS FOR THE RESTORATION OF A FECAL MICROBIOTA AND METHODS FOR MAKING AND USING THEM 审中-公开
标题翻译：用于恢复FECAL MICROBIOTA的组合物及其制备和使用它们的方法
公开(公告)号：WO2014078911A1
公开(公告)日：2014-05-30
申请号：PCT/AU2013/001362
申请日：2013-11-26
申请人： BORODY, Thomas Julius
发明人： BORODY, Thomas Julius
IPC分类号： A61K35/38 , A61P1/00 , C07K14/195
CPC分类号： A61K35/38 , A61K9/19 , A61K9/2004 , A61K31/341 , A61K31/4164 , A61K31/4439 , A61K31/485 , A61K31/606 , A61K31/635 , A61K31/655 , A61K31/706 , A61K35/74 , A61K35/741 , A61K35/742 , A61K35/744 , A61K35/745 , A61K35/747 , A61K35/76 , A61K36/28 , A61K36/31 , A61K36/48 , A61K36/8962 , A61K38/40 , A61K38/465 , A61K38/47 , A61K38/51 , A61K45/06 , A61K2300/00 , C12N1/20 , C12Y301/21001 , C12Y302/01 , C12Y302/01052 , Y02A50/473
摘要： In alternative embodiments, the invention provides compositions and methods for treating various disorders and conditions in mammals, including chronic disorders in which there is a presence of an abnormal microbiota or an abnormal distribution of microflora in the gastrointestinal tract. In alternative embodiments, the invention provides liquid preparations or formulations derived from a human fecal material (e.g., a stool) processed, e.g., filtered and/or centrifuged, such that all bacteria, fungal spores and viruses are removed, but retaining the native biologically active molecules from the fecal material and bacteriophages. In alternative embodiments, the invention provides a "rough-", "incomplete-" or medium- filtered microbiota which still comprises native physiological components or nutritive agents for the bacteria, e.g., retains native biologically and nutritionally active components. In alternative embodiments, the invention provides a highly filtered or substantially purified microbiota in combination with, or having added back, a liquid preparation or formulation of the invention. In alternative embodiments, the invention provides compositions or formulations where the bacteria, or microbiota, component has been cultured, or cultured under anaerobic conditions, or harvested, stored and/or cultured under anaerobic conditions. In alternative embodiments, the invention provides various additives, compositions and donor restrictions for treating these disorders and conditions.
摘要翻译：在替代实施方案中，本发明提供用于治疗哺乳动物中各种病症和病症的组合物和方法，包括其中在胃肠道中存在异常微生物群或微生物群落的异常分布的慢性病症。在替代实施方案中，本发明提供来自人类粪便物质（例如，粪便）的液体制剂或制剂，例如经过过滤和/或离心处理，使得除去所有细菌，真菌孢子和病毒，但保留天然生物学来自粪便物质和噬菌体的活性分子。在替代实施方案中，本发明提供了一种“粗”，“不完全”或中等过滤的微生物群，其还包含细菌的天然生理成分或营养剂，例如保留天然生物和营养活性成分。在替代实施方案中，本发明提供与本发明的液体制剂或制剂组合或加入的高度过滤或基本上纯化的微生物群。在替代实施方案中，本发明提供其中细菌或微生物组分已经在厌氧条件下培养或培养，或在厌氧条件下收获，储存和/或培养的组合物或制剂。在替代实施方案中，本发明提供用于治疗这些疾病和病症的各种添加剂，组合物和供体限制。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式